Drug Type ASO |
Synonyms nL-SCN2A-002 |
Target |
Mechanism Nav1.2 modulators(Sodium channel protein type II alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Genetic Diseases, Inborn | Phase 2 | US | 16 Feb 2024 |